CGEM

15.98

0.38% 0.06

Handel nachbörslich: 15.98

Cullinan Therapeutics Inc (CGEM)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$15.92

Offen:

$15.84

24-Stunden-Volumen:

363.44K

Relative Volume:

0.70

Marktkapitalisierung:

$926.47M

Einnahmen:

Nettoeinkommen (Verlust:

$-153.16M

KGV:

-4.7418

EPS:

-3.37

Netto-Cashflow:

$-134.48M

1W Leistung:

-5.56%

1M Leistung:

-2.20%

6M Leistung:

-43.63%

1J Leistung:

+61.09%

1-Tages-Spanne:

$15.15

$16.00

1-Wochen-Bereich:

$15.15

$16.79

52-Wochen-Spanne:

$7.64

$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Firmenname

Cullinan Therapeutics Inc

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

617-410-4650

Adresse

ONE MAIN STREET, CAMBRIDGE

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

CGEM's Discussions on Twitter

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-05-01	Eingeleitet	Stifel	Buy
2024-04-15	Eingeleitet	William Blair	Outperform
2024-02-15	Eingeleitet	Wedbush	Outperform
2023-06-15	Eingeleitet	TD Cowen	Outperform
2022-11-21	Eingeleitet	BTIG Research	Buy
2021-04-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-02-02	Eingeleitet	Evercore ISI	Outperform
2021-02-02	Eingeleitet	Morgan Stanley	Equal-Weight
2021-02-02	Eingeleitet	SVB Leerink	Outperform
2021-02-01	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten

07:16 AM

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan

07:16 AM

02:11 AM

Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com

02:11 AM

Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire

Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan

Nov 04, 2024

Nov 03, 2024

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat

Nov 03, 2024

Oct 30, 2024

FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat

Oct 30, 2024

Oct 24, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024

Oct 22, 2024

Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Oct 22, 2024

SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Oct 22, 2024

Oct 20, 2024

cullinan oncology, inc. Earnings dates - RTTNews

Oct 20, 2024

Oct 18, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 3.2%Here's Why - MarketBeat

Oct 18, 2024

Oct 17, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Update - MarketBeat

Oct 17, 2024

Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com

Oct 17, 2024

Oct 16, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 7%Here's Why - MarketBeat

Oct 16, 2024

Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 16, 2024

Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study - Marketscreener.com

Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire

Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - StockTitan

Oct 16, 2024

Oct 11, 2024

How did Cullinan Therapeutics Inc (CGEM) fare last session? - US Post News

Oct 11, 2024